e-learning
resources
Munich 2006
Tuesday 05.09.2006
Lung cancer staging and miscellaneous
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of vascular endothelial growth factor antisense oligonucleotides and low molecular weight heparin on pulmonary thromboembolism in mice with Lewis lung cancer
Y. Zhang, C. Wang, Z. Zhai (Beijing, China)
Source:
Annual Congress 2006 - Lung cancer staging and miscellaneous
Session:
Lung cancer staging and miscellaneous
Session type:
Oral Presentation
Number:
3543
Disease area:
Pulmonary vascular diseases, Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Zhang, C. Wang, Z. Zhai (Beijing, China). Effect of vascular endothelial growth factor antisense oligonucleotides and low molecular weight heparin on pulmonary thromboembolism in mice with Lewis lung cancer. Eur Respir J 2006; 28: Suppl. 50, 3543
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Effect of VEGF antisense oligonucleotides combined with low molecular weight heparin on the growth and metastasis of mice Lewis lung cancer
Source: Annual Congress 2007 - Biology in thoracic oncology
Year: 2007
The role of serum adhesion molecules and vascular endothelial growth factor in the treatment approach of the lung cancer patients
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009
Role of anti-proliferative therapy in PAH
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008
Vascular endothelial growth factor (VEGF) mRNA isoforms in an animal model of acute lung injury
Source: Annual Congress 2003 - Animal models of lung injury: useful or not?
Year: 2003
Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007
PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Hypoxia-induced increase in NO production and eNOS expression by murine pulmonary microvascular endothelial cells
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
The clininical value of vascular endothelial growth factor (VEGF) in the development of lung sarcoidosis.
Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes
Year: 2018
Changes and significance of hepatoma-derived growth factor and vascular endothelial growth factor in serum and lung tissue from patients with lung cancer
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
Tumor-related angiogenesis: role in tumour growth and metastasis formation
Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases
Year: 2005
Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer
Source: Eur Respir J 2002; 19: 557-570
Year: 2002
Gene therapeutic approaches: from stem cell therapy to gene delivery
Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine
Year: 2006
Serum levels of vascular endothelial growth factor in lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 77s
Year: 2004
Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 386s
Year: 2006
Imbalance between vascular endothelial growth factor and endostatin in emphysema
Source: Eur Respir J 2003 Oct 01;22(4):609-612
Year: 2003
The effects of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro
Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours
Year: 2008
Hypoxia-induced pulmonary artery fibroblast proliferation and migration is prevented by ASK1 inhibition in an in vitro cellular model of pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Expression of vascular endothelial-cadherin and vascular endothelial growth factor in non-small cell lung cancer and their clinical significances
Source: Annual Congress 2012 - New aspects of lung cancer biology
Year: 2012
Production of a novel isoform of vascular endothelial growth factor (VEGF) by the normal human lung
Source: Eur Respir J 2006; 28: Suppl. 50, 822s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept